Localized Renal Cell Carcinoma
Advertisement
Hans Hammers, MD, PhD – Driving Immunotherapy Combinations Into the Modern Age of Kidney Cancer Care
Dr. Hammers discusses the kidney clinical trials he has led and shares his perspectives on novel IO and targeted therapies.
The da Vinci Single Port platform allows robot-assisted surgical procedures with the same precision as multiport techniques.
While nephrectomy is a common treatment for kidney cancer, it can result in loss of kidney function or kidney failure.
The EVEREST trial analyzed the effectiveness of everolimus in patients with RCC who have undergone full surgical resection.
Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.
Several experts discuss the evolution of nephrectomy, how it is used today, which patients are best suited for it, and more.
To identify positive surgical margins, researchers used DESI-MSI to to distinguish normal tissue from RCC tissue samples.
Tumor grade, sarcomatoid features may influence outcomes with adjuvant nivo/ipi in patients with RCC after nephrectomy.
Partial nephrectomy has been gaining traction as an effective treatment for RCC due to its safety and efficacy.
Tumors with only a VHL mutation were associated with better outcomes compared with tumors containing additional mutations.
AUA guidelines for localized RCC have thermal ablation as an alternative modality. EAU guidelines are conflicting.
SAbR could potentially serve as a new noninvasive alternative treatment, but data on the procedure are limited.
A review of adjuvant therapies shows patient characteristics that may result in favorable treatment responses.
Steven Campbell, MD, PhD, overviews the surgical options available for patients with localized renal cell carcinoma.
Researchers presented the largest retrospective characterization of localized RCC with sarcomatoid dedifferentiation.
Matthew Zibelman, MD, highlights SOC adjuvant therapy for localized RCC and practice-changing potential of novel therapies.
A new study evaluated renal function outcomes for patients with oncocytoma managed with surveillance vs nephrectomy.
Guadecitabine may be well tolerated in patients with dSDH tumors, including HLRCC-RCC, according to results of a new study.
Cryoablation and heat-based thermal ablation represent alternative management options for frail and/or comorbid RCC patients.
Stereotactic body radiotherapy can benefit RCC patients deemed unfit for surgical therapy.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.